SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants
In this week’s View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Interventions and Imaging, Magnetic Resonance Imaging, Prevention, Vascular Medicine
Keywords: EaglesEyeView, Glucagon-Like Peptide 1, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Kidney Diseases, Ischemia, Diffusion Magnetic Resonance Imaging, Transcatheter Aortic Valve Replacement, Anticoagulants, Perioperative Medicine, Thromboembolism
